Wikisage, the free encyclopedia of the second generation, is digital heritage
Fabry disease: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (springer paper) |
||
| Line 7: | Line 7: | ||
[https://www.ncbi.nlm.nih.gov/pubmed/30064518 Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY] | [https://www.ncbi.nlm.nih.gov/pubmed/30064518 Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY] | ||
[https://link.springer.com/article/10.1007%2Fs12551-018-0432-5 Anderson-Fabry disease in heart failure] | |||
<references/> | <references/> | ||
Revision as of 00:46, 11 August 2018
Fabry disease is a genetic condition involving lysosomal storage (E75.2)[1]is an X-linked disorder caused by alpha-galactosidase A deficiency [2]
migalastat or 1-deoxygalactonojirimycin received an orphan drug approval [3]